Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
The Big Pharma would gain ex-U.S. rights to the potentially disease-modifying treatment for chronic kidney disease, excluding some Asian markets.
The Big Pharma would gain ex-U.S. rights to the potentially disease-modifying treatment for chronic kidney disease, excluding some Asian markets.